M&A and Fundraising Analysis for October 31, 2026

Fractile raises £577M to build the inference chips the UK didn't have

Source: google.com → · Sector The Physical World — 📬 subscribe to the The Physical World newsletter

Fractile, a British startup specializing in semiconductor design, closed a £577.4 million Series C, according to share filings registered with Companies House between September and October 2026.

But the more interesting fact is structural. Designing chips is a business with extreme increasing returns: development costs are fixed and colossal, while marginal production costs are almost zero once the design is validated. A startup reaching this stage with this level of funding is not looking to survive — it's looking to lock in a position before established players (Nvidia, AMD, new entrants like Groq or Tenstorrent) close all windows. £577M is the minimum entry price to play in this league.

What this round primarily reveals is that significant investors have decided that the inference market — running AI models at scale, not training them — is distinct and large enough to justify a dedicated champion. For a French industrialist or operator deploying AI in production, the question of which physical architecture their infrastructure runs on is no longer abstract: it becomes a strategic choice.

ALLOX maps proteins that conventional chemistry cannot target

Source: google.com → · Sector Biotech & Pharma — 📬 subscribe to the Biotech & Pharma newsletter

ALLOX (legal name: Allostery Exploration Technologies), a spin-out from the Centre for Genomic Regulation in Barcelona, is developing a platform that combines high-throughput genetics, experimental biology, and artificial intelligence to identify drug binding sites on proteins that classical methods cannot reach — notably protein-protein interactions and transcription factors, involved in cancers and inflammatory diseases. The company raised $10.5M in seed funding (approximately €9.5M), a round led by Asabys Partners through its Sabadell Asabys II fund, with participation from CDTI (the Spanish public agency for industrial technology, via its SICC Innvierte vehicle) and Institut Català de Finances.

The funds will go towards expanding the platform, developing proprietary AI models capable of predicting therapeutic opportunities from large-scale biophysical data, strengthening the internal discovery team, and advancing several programs towards proprietary small molecule candidates. ALLOX also plans research collaborations with pharma and biotech partners.

The continuity of investors is notable: Asabys and CDTI were already present in the pre-seed round in December 2023. This is not an external conviction round — it's a follow-on from insiders who have known the technology from the beginning, which reduces the usual information asymmetry at this stage.

The real question for a pharma industrial partner is this: if the platform delivers on its promise — measuring the activity of a million mutant versions of a protein in a single experiment — it's not selling a research service, it's selling certainty on targets that no one else can validate. It's a pipeline asset, not a service provider.